Olivier Brandicourt - Sanofi CEO, Director and Member of Strategy Committee

SNYNF Stock  USD 97.65  2.05  2.06%   

CEO

Mr. Olivier Brandicourt was appointed to serve as Chairman of the Executive Committee, Chief Executive Officer, Director of Sanofi S.A. as of May 4, 2015 until September 1, 2019. He was appointed as Member of the Strategy Committee of the Company. He was Chairman of the Executive Committee, Chief Executive Officer of the Company from April 2, 2015 to May 4, 2015. He has 28 years of global experience in the pharmaceutical industry. He joined the Company after serving as Chief Executive Officer of Bayer Healthcare AG since 2013. He is Member of the Board of Management of the Pharmaceutical Research and Manufacturers of America Member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations Member and VicePresident of the European Federation of Pharmaceutical Industries and Associations. He worked at Pfizer for 13 years, where he most recently served as Member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units. Over his career at Pfizer, he served in a series of leadership positions, including heading its Global Primary Care business unit from 2009 to 2012 and its Global Specialty Care business unit from 2008 to 2009. He also led its Cardiology business in the United States since 2015.
Age 62
Tenure 9 years
Phone33 1 53 77 40 00
Webhttps://www.sanofi.com
Brandicourt started his career as a Medical Director for the Region Africa at WarnerLambert/ParkeDavis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada. He is also an Honorary Member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. He studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds an Advanced Degree in Cellular and Immunological Pathophysiology from Universite Paris V Rene Descartes. He also holds a Master’s Degree in Biology .

Sanofi Management Efficiency

The company has return on total asset (ROA) of 0.0607 % which means that it generated a profit of $0.0607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0959 %, meaning that it generated $0.0959 on every $100 dollars invested by stockholders. Sanofi's management efficiency ratios could be used to measure how well Sanofi manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 14.86 B in total debt with debt to equity ratio (D/E) of 0.3, which may suggest the company is not taking enough advantage from borrowing. Sanofi has a current ratio of 1.27, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sanofi until it has trouble settling it off, either with new capital or with free cash flow. So, Sanofi's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sanofi sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sanofi to invest in growth at high rates of return. When we think about Sanofi's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

CEO Age

Graham BriggsHarmony Gold Mining
61
John MacFarlaneSonos Inc
40
Johannes HeerdenHarmony Gold Mining
45
Richard ZimmermanCedar Fair LP
63
Christopher RondeauPlanet Fitness
51
Peter SteenkampHarmony Gold Mining
63
Matthew OuimetCedar Fair LP
62
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 95442 people. Sanofi [SNYNF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Sanofi Leadership Team

Elected by the shareholders, the Sanofi's board of directors comprises two types of representatives: Sanofi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi's management team and ensure that shareholders' interests are well served. Sanofi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Roy Papatheodorou, Gen VP
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Dieter Weinand, Executive Vice President Member of the Executive Board
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
Eva SchaeferJansen, Head Relations
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Bernard Charles, Independent Director
Melanie Lee, Independent Director
Pierre Chancel, Sr Marketing
Christophe Babule, Director
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee
Laurent Attal, Director
JeanRene Fourtou, Independent Director
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee
Josephine Fubara, Chief Care
Christian Mulliez, Director
Robert Castaigne, Independent Director
Laurent Gilhodes, Principal Accounting
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director
Josep Catlla, Head Communications
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Paul Hudson, CEO Director
Bruno Mnard, Chief officer
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Dante Beccaria, Global VP
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Diane Souza, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director

Sanofi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sanofi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sanofi in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sanofi's short interest history, or implied volatility extrapolated from Sanofi options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Sanofi Pink Sheet analysis

When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Please note, there is a significant difference between Sanofi's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.